Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
Background
Cited by
Items 301–400 of 560
Anti‐inflammatory role of glucose‐dependent insulinotropic polypeptide in periodontitis
Suzuki, Y., Nakamura, N., Miyabe, M., Nishikawa, T., Miyajima, S., Adachi, K., Mizutani, M., Kikuchi, T., Miyazawa, K., Goto, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12450 · Cited by 27
Chen, B., Zhao, W., Jia, Q., Zhou, W., Bu, Y., Wang, Z.-Z., Wang, F., Wu, W., & Wang, Q. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224293 · Cited by 25
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Myeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 27
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
Dicembrini, I., Pala, L., & Rotella, C. M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/898913 · Cited by 26
“Similar inhibitory effects on vascular cell adhesion molecule1 (VCAM-1) and hsCRP have been reported for exenatide [27, 28].”
BackgroundEndogenous Bioactive Peptides as Potential Biomarkers for Atherosclerotic Coronary Heart Disease
Watanabe, T., Sato, K., Itoh, F., Wakabayashi, K., Shichiri, M., & Hirano, T. (2012) · Sensors · doi:10.3390/s120404974 · Cited by 26
Understanding the Cardiovascular Effects of Incretin
Yoon, J. S., & Lee, H. W. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.437 · Cited by 25
“[26] reported that the GLP-1R was abundantly expressed in monocytes/macrophages.”
BackgroundWang, Y. Y., Wang, Y., Qi, X.-Y., Liao, Z., Mai, Y.-N., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839849 · Cited by 30
“org 5 in response to nutrient ingestion, has attracted much attention because of its mimetics for the treatment of obesity (69), lowering glucose levels, and improving insulin sensitivity in individuals with type 2 diabetes and in animal models (70).”
BackgroundSharbatdar, Y., Mousaviyan, R., Varnosfaderani, S. M. N., Aziziyan, F., Liaghat, M., Baziyar, P., Rad, A. Y., Tavakol, C., Moeini, A. M., Nabi‐Afjadi, M., et al. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01215-y · Cited by 25
“Exendin 4, a GLP1 analog, greatly reduced monocyte and macrophage levels in the arterial wall in atherosclerosis animal models and inhibited atherogenesis by controlling inflammation in macrophages (Arakawa et al. 2010).”
BackgroundIncretin hormones as immunomodulators of atherosclerosis
Alonso, N., Julián, M. T., Puig‐Domingo, M., & Vives‐Pi, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00112 · Cited by 25
“This effect seems to be mediated, at least in part, by suppressing the inflammatory response in macrophages through the activation of the cAMP/PKa pathway which inhibits the expression of TNF-α and the monocyte chemoattractant protein-1 (MCP-1) in activated macrophages (Arakawa et al., 2010).”
BackgroundKimura, T., Obata, A., Shimoda, M., Okauchi, S., Hirukawa, H., Kohara, K., Kinoshita, T., Nogami, Y., Nakanishi, S., Mune, T., et al. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117725898 · Cited by 24
Hirukawa, H., Kaneto, H., Shimoda, M., Kimura, T., Okauchi, S., Obata, A., Kohara, K., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.010 · Cited by 25
“In addition, since Ex-4 is well known to have long-term effects and has been used in various experiments (Tamaki et al., 2010, Arakawa et al., 2010), its usefulness was already established.”
BackgroundThe Incretin Axis in Cardiovascular Disease
Plutzky, J. (2011) · Circulation · doi:10.1161/circulationaha.111.064139 · Cited by 27
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 24
Younce, C. W., Niu, J., Ayala, J., Burmeister, M. A., Smith, L. H., Kolattukudy, P. E., & Ayala, J. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.022 · Cited by 26
Ma, G., Chen, S., Yin, L., Gao, X., & Yao, W. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.128 · Cited by 23
Qiu, Y., Deng, X., Sha, Y., Wu, X., Zhang, P., Chen, K., Zhao, Z., Wei, W., Yang, L., Yuan, G., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s284420 · Cited by 23
Takahashi, H., Nomiyama, T., Terawaki, Y., Kawanami, T., Hamaguchi, Y., Tanaka, T., Tanabe, M., Bruemmer, D., & Yanase, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.43414 · Cited by 22
Self-citationThe Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases
García, R. D., Asensio, J. A., Perdicaro, D. J., & Peral, M. D. L. Á. (2022) · Current Vascular Pharmacology · doi:10.2174/1570161120666220201160038 · Cited by 22
Erdogdu, Ö., Eriksson, L., Nyström, T., Sjöholm, Å., & Zhang, Q. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.106 · Cited by 22
The Impact of Current and Novel anti-diabetic Therapies On Cardiovascular Risk
Ussher, J. R., Sutendra, G., & Jaswal, J. S. (2012) · Future Cardiology · doi:10.2217/fca.12.68 · Cited by 21
“Furthermore, GLP-1R activation is associated with favorable effects on atherosclerotic progression, as a 28 day continuous infusion of exendin-4 in C57BL/6 and ApoE-deficient mice reduced monocyte adhesion to aortic endothelial cells and was associated with a reduction in atherosclerotic lesion size [72].”
BackgroundExendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension
Roan, J., Hsu, C., Fang, S., Tsai, H.-W., Luo, C.-Y., Huang, C.-C., & Lam, C.-F. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.10.085 · Cited by 22
“It also suppresses inflammatory cytokine generation by activating adenylate cyclase and the production of cyclic adenosine monophosphate (cAMP) in monocytes and macrophages.(11) Furthermore, Ex4 attenuates hyperoxide-induced senescence in cultured vascular smooth muscle cells (VSMCs).”
BackgroundGreco, R., Demartini, C., Zanaboni, A., Tumelero, E., Candeloro, E., Persico, A., Morotti, A., Amantea, D., & Tassorelli, C. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00851-8 · Cited by 21
Jensen, S. B. K., Lundgren, J. R., Janus, C., Juhl, C. R., Olsen, L. M., Rosenkilde, M., Holst, J. J., Stallknecht, B. M., Madsbad, S., & Torekov, S. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031431 · Cited by 20
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Ståhle, M. R., Kytö, V., Kiugel, M., Liljenbäck, H., Metsälä, O., Käkelä, M., Li, X., Oikonen, V., Saukko, P. J., Nuutila, P., et al. (2018) · Journal of Nuclear Cardiology · doi:10.1007/s12350-018-01547-1 · Cited by 22
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 21
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Katakami, N., Mita, T., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.18333 · Cited by 19
Self-citationPotential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice
He, L., Law, P. T. Y., Wong, C. K., Chan, J. C. N., & Chan, P. K. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-01952-5 · Cited by 20
Honda, J., KIMURA, T., Sakai, S., Maruyama, H., Tajiri, K., Murakoshi, N., Homma, S., MIYAUCHI, T., & Aonuma, K. (2018) · Physiological Research · doi:10.33549/physiolres.933822 · Cited by 20
“Recently, GLP-1R agonists were reported to inhibit endothelial dysfunction (Gaspari et al. 2013), inflammation (Liu et al. 2009, Arakawa et al. 2010), and cell proliferation (Goto et al. 2011).”
BackgroundInteractions between diabetes and COVID-19: A narrative review
Sabri, S., Bourron, O., Phan, F., & Nguyen, L. S. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i10.1674 · Cited by 22
Wu, L., Liu, X., Wang, L.-X., Wang, Y., Wang, L., Guan, B., Chen, Z., & Liu, L. (2016) · Endocrine · doi:10.1007/s12020-016-1190-4 · Cited by 20
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
“[123] Mice, wire-mediated endovascular injury: femoral artery analysis.”
InfluentialHan, Y., Xu, H., Yao, X., Li, Z., Zhu, C., Li, X., Chen, B., & Sun, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1737662 · Cited by 23
Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00560-z · Cited by 18
“Previously, we have reported a vascular protective effect of GLP-1R agonist exendin-4 (Ex-4) using atheroma formation in an atherosclerotic apoE−/− mouse model [6] and intimal thickness after vascular guide wire injury [7, 8].”
BackgroundSelf-citationCrosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
da Silva, E. M., Yariwake, V. Y., Alves, R. W., de Araújo, D. R., & Andrade‐Oliveira, V. (2022) · Peptides · doi:10.1016/j.peptides.2022.170834 · Cited by 18
Mita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Onuma, T., Kuribayashi, N., Osonoi, T., Kaneto, H., Kosugi, K., Umayahara, Y., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-35 · Cited by 20
“GLP-1 directly acts on endothelial cells, vascular smooth muscle cells, monocytes, macrophages, and lymphocytes, and GLP-1 and GLP-1 receptor agonists have been shown to inhibit atherosclerosis and inflammation in rodents [24-26].”
BackgroundSelf-citationVargas-Sánchez, K., Vargas, L., Urrutia, Y., Beltrán, I., Rossi, A. B., Lozano, H. Y., Guarín, J., & Losada-Barragán, M. (2020) · Journal of Inflammation · doi:10.1186/s12950-020-00264-2 · Cited by 18
“Otherwise, non-canonical functions of GLP-1R are reported in some lineages of immune cells, such as an immunomodulatory role in the migration and differentiation of T and B lymphocytes [12, 47, 48], and a reduction in monocyte/macrophage migration and in ammatory cytokine production [49, 50].”
BackgroundCariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues
Chen, B., Zhao, W., Dong, J., & Si-Ma, H. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3302-7 · Cited by 19
“It was recently reported that GLP-1 receptor agonists (exenatide or exendin-4) reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages and attenuated atherosclerosis [43].”
BackgroundIwaya, H., Lee, J. S., Yamagishi, S., Shinoki, A., Lang, W., Thawornkuno, C., Kang, H.-K., Kumagai, Y., Suzuki, S., Kitamura, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050658 · Cited by 19
Htike, Z. Z., Yates, T. E., Brady, E. M., Webb, D. R., Gray, L. J., Swarbrick, D. J., McCann, G. P., Khunti, K., & Davies, M. J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0421-6 · Cited by 19
Shen, W.-R., Kitaura, H., Qi, J., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., & Mizoguchi, I. (2020) · The Angle Orthodontist · doi:10.2319/021320-103.1 · Cited by 19
Fan, W., Zhang, Q., Wang, C., Sun, J., Zhang, J., & Yin, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114390 · Cited by 17
Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis
Kissow, H. (2015) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000132 · Cited by 18
Mišúth, S., Uhrinová, M., Klimas, J., Vavrincová-Yaghi, D., & Vavrinec, P. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106855 · Cited by 17
Mita, T., Goto, H., Azuma, K., Jin, W. L., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.031 · Cited by 17
Self-citationFrom diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
Sano, H., Terasaki, J., Murase‐Mishiba, Y., Imagawa, A., & Hanafusa, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.020 · Cited by 16
“Since macrophages express GLP-1 receptors [20], we hypothesized that chemical mediators, such as TNFa, IL-1b, and iNOS, from infected macrophages play a pivotal role in the destruction of b-cells and that exendin-4 modulates the expression of these mediators.”
BackgroundHachuła, M., Basiak, M., Kosowski, M., & Okopień, B. (2024) · Life · doi:10.3390/life14060690 · Cited by 18
“Additional studies, especially randomized clinical trials with long-term observation, are needed to un-questionably assess the effect of this group of drugs on the development of atherosclerotic cardiovascular disease.”
BackgroundProtective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Ma, X., Lu, R., Gu, N., Wei, X., Bai, G., Zhang, J., Deng, R., Feng, N., Li, J., & Guo, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1054192 · Cited by 15
“infarct areas in ischemia-reperfusion heart models (pig and mouse) [7], increase coronary blood flow in isolated mouse heart [4], and reduce monocyte adhesion and atherosclerotic lesions in apoE mice [8].”
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
Ahn, C. H., & Lim, S. K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00038 · Cited by 14
Incretin Therapy and Heart Failure
Oyama, J., & Node, K. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1561 · Cited by 15
“42 For diabetic vascular and endothelial injury,43 substantial data exist regarding the beneficial effects of GLP-1 and related drugs on endothelial function and the incidence of atherosclerosis, including (1) increasing the eNOS expression,44,45 (2) increasing the number of endothelial progenitor cells (EPCs),46 (3)…”
Potential cardioprotective action of GLP-1: from bench to bedside
Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14
Zhang, Q., Hao, J.-W., Li, G., Ji, X.-J., Yao, X., Dong, N., & Yao, Y.-M. (2017) · Inflammation Research · doi:10.1007/s00011-017-1104-9 · Cited by 15
Hormone treatments in congestive heart failure
Lei, L., & Mao, Y. (2018) · Journal of International Medical Research · doi:10.1177/0300060518761262 · Cited by 14
Alharby, H., Abdelati, T., Rizk, M. M., Youssef, E. A., Gaber, N., Moghazy, K., & Yafei, S. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.031 · Cited by 15
Yasunari, E., Mita, T., Osonoi, Y., Azuma, K., Goto, H., Ohmura, C., Kanazawa, A., Kawamori, R., Fujitani, Y., & Watada, H. (2014) · Endocrinology · doi:10.1210/en.2013-1628 · Cited by 14
“The supernatants were subjected to western blot analysis using antiglyceraldehyde-3-phosphate dehydrogenase antibody, anti-ERK antibody, anti-p-ERK antibody, p-retinoblastoma protein (all from Cell Signaling Technology), anticyclin D1 antibody (Millipore), and anti-cyclinE antibody (Upstate Chemicon) as described prev…”
MethodSelf-citationGLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“This Review summarizes the effects of GLP-1 and GLP-1RAs in the CV system as well as clinical data of GLP-1RAs in individuals with CV disease or high CV risk. mice on an HCD not only showed smaller atherosclerotic lesions but also a more than 50% reduction in blood leukocytes, including Ly-6C hi monocytes and neutroph…”
Testis–Gut‐Reproduction Axis: The Key to Reproductive Health
Zou, H., Chen, W., Hu, B., Liu, H., & Zhao, J. (2024) · Andrologia · doi:10.1155/2024/5020917 · Cited by 15
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Wu, S. S., Sun, F., Zhang, Y., Yang, Z., Hong, T., Chen, Y., & Zhan, S. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12102 · Cited by 13
Tsurutani, Y., Omura, M., Matsuzawa, Y., Saito, J., Higa, M., Taniyama, M., & Nishikawa, T. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2016.12.002 · Cited by 13
Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats
Шекунова, Е. В., Кашкин, В. А., Muzhikyan, A., Макарова, М. Н., Balabanyan, V. Y., & Makarov, V. G. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172835 · Cited by 13
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Ji, L., He, X., Min, X., Yang, H., Wu, W., Xu, H., Chen, J., & Mei, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465881 · Cited by 12
Nakajima, K., Mita, T., Osonoi, Y., Azuma, K., Takasu, T., Fujitani, Y., & Watada, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/406394 · Cited by 12
“Thus, one of themain goals ofmanagement of T2DM is to reduce the onset of CVD.”
Self-citationSingh, V., Jain, M. K., Prakash, P., Misra, A., Khanna, V., Tiwari, R. L., Keshari, R. S., Singh, S. V., Dikshit, M., & Barthwal, M. K. (2011) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-010-0065-z · Cited by 12
“Moreover, glucagon-like peptide-1 receptor agonist exendin-4 reduced plasma total cholesterol without affecting LDLC and HDLC cholesterol levels [4].”
BackgroundStåhle, M. R., Hellberg, S., Virta, J., Liljenbäck, H., Metsälä, O., Li, X., Jauhiainen, M., Saukko, P. J., Ylä‐Herttuala, S., Nuutila, P., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2020 · Cited by 13
Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Díaz, L. J., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Diagnostics · doi:10.3390/diagnostics11081431 · Cited by 12
“Preclinical data, primarily in mice, have demonstrated that GLP-1 RAs inhibit the formation of atherosclerotic plaques [12,19], suppress macrophage-derived foam cell formation in the plaques [14] and decrease the adhesion of mononuclear cells to the vessel wall [15].”
BackgroundZhang, Y., Li, Z., & Hao, Y. (2025) · European journal of medical research · doi:10.1186/s40001-024-02241-4 · Cited by 13
“While GLP-1 RAs’ cardiovascular benefits mainly lie in their antiinflammatory and antiatherogenic effects that restrain atherosclerotic lesions and affect blood pressure regulation [28–30].”
Stroke in the Patient With Type 2 Diabetes
Jerkins, T. W., & Bell, D. S. H. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.01.010 · Cited by 11
Sardu, C., Marfella, L. V., Fumagalli, C., Rinaldi, L., Sasso, F. C., Cozzolino, D., Nappo, F., Sellitto, A., Romano, C. P., Carusone, C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209977 · Cited by 13
Wójcicka, G., Pradiuch, A., Fornal, E., Stachniuk, A., Korolczuk, A., Marzec‐Kotarska, B., Nikolaichuk, H., Czechowska, G., Kozub-Pędrak, A., Trzpil, A., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115637 · Cited by 11
Suzuki, K., Watanabe, K., Suzuki, T., Ouchi, M., Futami‐Suda, S., Igari, Y., Nakano, H., & Oba, K. (2012) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2012.23053 · Cited by 14
Nozue, T., Fukui, K., Koyama, Y., Fujii, H., Kunishima, T., Hikita, H., Hibi, K., Miyazawa, A., & Michishita, I. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0662-4 · Cited by 11
“Several studies have shown that GLP-1 receptor agonists have an anti-atherogenic effect that is associated with a reduction in adhesion molecules and the prevention of inflammation [16, 17].”
BackgroundProtective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage
Guo, L., Qiao, Y., Zhang, L., & Pan, Q. (2015) · Medicine · doi:10.1097/md.0000000000002055 · Cited by 11
GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
Self-citationMita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Gosho, M., Shimomura, I., & Watada, H. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1925305 · Cited by 11
Self-citationHorikawa, Y., Enya, M., Iizuka, K., Chen, G. Y., Kawachi, S.-I., Suwa, T., & Takeda, J. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00081.x · Cited by 11
Incretin attenuates diabetes-induced damage in rat cardiac tissue
Elbassuoni, E. (2014) · The Journal of Physiological Sciences · doi:10.1007/s12576-014-0327-6 · Cited by 12
“1, including the cardiovascular system as GLP-1 receptors are also found in endothelial cells, vascular smooth muscle cells, monocytes–macrophages of the vascular wall [10], and in the heart [11].”
BackgroundNozue, T., Fukui, K., Koyama, Y., Fujii, H., Kunishima, T., Hikita, H., Hibi, K., Miyazawa, A., & Michishita, I. (2016) · PubMed · Cited by 11
Anti-inflammatory properties of antidiabetic agents
Xourgia, E., Tzouganatou, E.-M., Papazafiropoulou, A. K., & Melidonis, A. I. (2019) · World Journal of Meta-Analysis · doi:10.13105/wjma.v7.i4.129 · Cited by 12
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Stabilizing Cellular Barriers: Raising the Shields Against COVID-19
Hanchard, J., Capó-Vélez, C. M., Deusch, K., Lidington, D., & Bolz, S.-S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.583006 · Cited by 10
“, ICAM-1 and VCAM-1) (103, 113), (iii) reducing immune cells cytokine production (113), and (iv) attenuating endothelial cell oxidative stress (114).”
BackgroundDiabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
Krizhanovskii, C., & Franco‐Cereceda, A. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180828155622 · Cited by 11
Wójcicka, G., Zaręba, M., Warpas, A., Jamróz-Wiśniewska, A., Rusek, M., Czechowska, G., & Bełtowski, J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.014 · Cited by 10
Wang, B., Ni, Y., ZHONG, J., & Sun, F. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00167.x · Cited by 11
Bloch, O., Perl, S. H., Lazarovitch, T., Yovel, D. Z., Love, I., Mendel‐Cohen, L., Goltsman, G., Flor, H., & Rapoport, M. J. (2020) · Shock · doi:10.1097/shk.0000000000001683 · Cited by 12
“However, the GLP-1 receptor expression on CD14 monocytes and macrophages in healthy humans (22) suggests that GLP-1 may directly inhibit their over activated pro-inflammatory response in early stage of Gram-negative sepsis.”
BackgroundInfluentialVirta, J., Hellberg, S., Liljenbäck, H., Ståhle, M. R., Silvola, J. M. U., Huusko, J., Söderström, M., Knuuti, J. M., Nuutila, P., Ylä‐Herttuala, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.029 · Cited by 10
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Vieira, I. H., Carvalho, T., Saraiva, J. C., Gomes, L., & Paiva, I. (2024) · Biomedicines · doi:10.3390/biomedicines12051102 · Cited by 9
“Beneficial effects on atherosclerotic plaque have been supported by several preclinical studies [45,46], as well as by data suggesting that liraglutide decreases the medial thickness of the carotid intimal layer [47].”
BackgroundRECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15652 · Cited by 11
“34,35 42 The mechanisms underlying the renoprotective effects of SGLT2 inhibitors and GLP-1RAs are partially different, so the combination of these agents may have synergistic effects.”
Paul, S., Maggs, D., Klein, K., & Best, J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12208 · Cited by 9
IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall
Mita, T., Azuma, K., Goto, H., Jin, W. L., Arakawa, M., Nomiyama, T., Suzuki, R., Kubota, N., Tobe, K., Kadowaki, T., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.10.086 · Cited by 9
Self-citationKaneto, H., Obata, A., Kimura, T., Shimoda, M., Sanada, J., Fushimi, Y., Katakami, N., Matsuoka, T., & Kaku, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249444 · Cited by 9
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.